Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa. [electronic resource]
- PharmacoEconomics Apr 2016
- 403-17 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1179-2027
10.1007/s40273-015-0356-x doi
Antiviral Agents--economics Benzimidazoles--economics Cost-Benefit Analysis Drug Costs Drug Therapy, Combination--economics Fluorenes--economics Genotype Hepacivirus--genetics Hepatitis C, Chronic--drug therapy Interferon-alpha--economics Markov Chains Models, Statistical Polyethylene Glycols--economics Quality-Adjusted Life Years Recombinant Proteins--economics Ribavirin--economics Sofosbuvir South Africa Uridine Monophosphate--analogs & derivatives